Subscribe To
Eiger biopharmaceuticals, inc. (eigr) ceo david cory on q1 2022 results - earnings call transcript
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vi...
May 8, 2022, 9:21 am
Applied therapeutics to present at the 43rd annual meeting of the society for inherited metabolic disorders
NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeli...
April 4, 2022, 7:30 am
Clarus therapeutics to report fourth quarter and full year 2021 financial and operating results
NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicat...
March 29, 2022, 4:05 pm
Axcella to report fourth quarter and year end 2021 financial results on march 30, 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to ...
March 23, 2022, 7:02 am
Wellbeing digital sciences says kgk science clinical study for shakeology validates weight loss benefits
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc, a healthcare company focused on clinical solutions and contract research, revealed that a ...
March 22, 2022, 9:26 am
Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder
The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in adults with pyruvate kinase (PK) deficienc...
February 18, 2022, 5:41 am
Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder
The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in adults with pyruvate kinase (PK) deficienc...
February 18, 2022, 5:41 am
Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder
The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in adults with pyruvate kinase (PK) deficienc...
February 18, 2022, 5:41 am
Viking therapeutics' early stage trial on fda hold in rare metabolic disorder
The FDA has placed a clinical hold on Viking Therapeutics Inc's (NASDAQ: VKTX) Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystr...
January 24, 2022, 7:33 am
Viking therapeutics' early stage trial on fda hold in rare metabolic disorder
The FDA has placed a clinical hold on Viking Therapeutics Inc's (NASDAQ: VKTX) Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystr...
January 24, 2022, 7:33 am
Viking therapeutics' early stage trial on fda hold in rare metabolic disorder
The FDA has placed a clinical hold on Viking Therapeutics Inc's (NASDAQ: VKTX) Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystr...
January 24, 2022, 7:33 am
Kaleido biosciences to present updated data of kb295 in ulcerative colitis at the 2022 crohn's and colitis congress
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, ...
January 21, 2022, 11:04 am
Kaleido biosciences to present updated data of kb295 in ulcerative colitis at the 2022 crohn's and colitis congress
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, ...
January 21, 2022, 11:04 am
Kaleido biosciences to present updated data of kb295 in ulcerative colitis at the 2022 crohn's and colitis congress
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, ...
January 21, 2022, 11:04 am
Akero therapeutics to present at the evercore isi 4th annual healthconx virtual conference
SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational...
November 26, 2021, 5:28 pm
Akero therapeutics to present at the evercore isi 4th annual healthconx virtual conference
SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational...
November 26, 2021, 5:28 pm
Akero therapeutics to present at the evercore isi 4th annual healthconx virtual conference
SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational...
November 26, 2021, 5:28 pm
Novo nordisk enhances metabolic disorder pipeline with rnai drug maker dicerna
Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as No...
November 18, 2021, 8:14 pm
Novo nordisk enhances metabolic disorder pipeline with rnai drug maker dicerna
Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as No...
November 18, 2021, 8:14 pm
Novo nordisk enhances metabolic disorder pipeline with rnai drug maker dicerna
Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as No...
November 18, 2021, 8:14 pm